Keywords
Abstract
Arterial hypertension is still a disease that continues to degrade the life’s quality worldwide and increases the number of deaths. Today, there are a large number of drugs aimed to treat hypertension, but not all of them are 100 % effective, because there are a large number of targets involved in the occurrence of pathologies. Scientists are still actively searching for both new targets and drugs, and methods of delivering them exactly to the target.
Vascular dysfunction leads to a number of extremely serious diseases, such as heart attack or stroke, as well as to a large number of disorders in the body, which significantly reduces the quality of life. The study of this issue is extremely important for the prevention the main disease in the future, reducing the
level of population disability and increasing lifetime.
The main advantages of pharmacogenomics are: the creation of more effective and less harmful specific drugs based on proteins, enzymes and RNA molecules associated with genes and diseases; increase the effectiveness of treatment; dosage according to age, weight and according to an individual set of genes; reducing the likelihood of occurrence/development of genetic diseases; creation of vaccines based on DNA or RNA, which activate the immune system and are not able to cause infection process, would be inexpensive and stable.
RNA interference is a clear example of how natural processes have been used as a tool for research and therapy. This method can be used as a tool for screening, and as the latest therapeutic tool. It was found that the use of RNA interference to suppress gene expression causes a long and stable interference effect, which is manifested in a significant reduction in gene expression.
Today, pharmacogenomics is at the stage of active development, which allows at a new level to provide therapy for diseases of various origins. Recently, great attention has been paid to the study of mechanisms of vascular tone regulation and involving pathways that are not directly related to changes in the concentration of calcium ions and which play a significant role in the formation of vascular tone. Hypertension has a large number of targets for therapeutic effects, so it is extremely important to use high-precision drugs.
The results of numerous studies suggest that the key role of PKС is in the regulation of myogenic tone of blood vessel walls both under normal physiological conditions and, especially, under development of hypertensive conditions of various genesis. Evidence of this is that inhibition of gene expression of the δ-isoform of PKС leads to a significant decrease in blood pressure in rats, which lasts for a week. To date, among the pharmacological agents for the hypertension treatment, there are no drugs which action is aimed to suppress PKC in the vascular wall. Research in this area may lead to the creation of new classes of pharmacological agents. And the application of pharmacogenomics in the form of RNA interference with the help of plasmid vectors can become
the tool that researchers around the world have been looking for many years.